Blueberry Therapeutics have unique nanopolymer drug delivery technology... ...which opens up huge opportunities to rapidly develop new medicines... ...and helps us find ways to treat dermatological disorders.
The Blueberry Therapeutics project team along with CEO John Ridden, and their partner Iqvia Biotech, held an Investigator meeting [...]
Susan Yau2019-11-15T13:42:27+00:00November 15th, 2019|
A Blueberry case study
In this video, CEO John Ridden and CSO David Cook talk about the early days of Blueberry Therapeutics, the short term and long term plans for the company, and the benefits of being based at Alderley Park, Cheshire.